Company intelligence / Profile preview

DICE Therapeutics

South San Francisco, California, United Statesdicetherapeutics.com ↗

Ownership: Private
Employees: ~32
Development stage: Phase 3

Overview

DICE Therapeutics developed oral small molecule inhibitors targeting the IL‑17 pathway for autoimmune and inflammatory diseases. Its lead program, DC‑806, advanced to Phase II trials in moderate-to-severe plaque psoriasis but was discontinued by Eli Lilly after acquisition. The follow-up candidate, DC‑853—designed for improved potency and metabolic stability—has become the new focus and has entered Phase II clinical trials. The company’s proprietary DELSCAPE platform enables discovery of oral drugs against challenging protein-protein interaction targets[6][8].

Therapeutic areas: ImmunologyDermatology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

simepdekinra

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on DICE Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DICE Therapeutics.

Explore the full profile